 |
|
Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus
The D:A:D Study
The Data Collection on Adverse Events of Anti-HIV Drugs Study Group*
Arch Intern Med. 2006;166:1632-1641.
Background An increasing proportion of deaths among human immunodeficiency virus (HIV)–infected persons with access to combination antiretroviral therapy (cART) are due to complications of liver diseases.
Methods We investigated the frequency of and risk factors associated with liver-related deaths in the Data Collection on Adverse Events of Anti-HIV Drugs study, which prospectively evaluated 76 893 person-years of follow-up in 23 441 HIV-infected persons. Multivariable Poisson regression analyses identified factors associated with liver-related, AIDS-related, and other causes of death.
Results There were 1246 deaths (5.3%; 1.6 per 100 person-years); 14.5% were from liver-related causes. Of these, 16.9% had active hepatitis B virus (HBV), 66.1% had hepatitis C virus (HCV), and 7.1% had dual viral hepatitis co-infections. Predictors of liver-related deaths were latest CD4 cell count (adjusted relative rate [RR], 16.1; 95% confidence interval [CI], 8.1-31.7 for <50 vs  500/µL), age (RR, 1.3; 95% CI, 1.2-1.4 per 5 years older), intravenous drug use (RR, 2.0; 95% CI, 1.2-3.4), HCV infection (RR, 6.7; 95% CI, 4.0-11.2), and active HBV infection (RR, 3.7; 95% CI, 2.4-5.9). Univariable analyses showed no relationship between cumulative years patients were receiving cART and liver-related death (RR, 1.00; 95% CI, 0.93-1.07). Adjustment for the most recent CD4 cell count and patient characteristics resulted in an increased risk of liver-related mortality per year of mono or dual antiretroviral therapy before cART (RR, 1.09; 95% CI, 1.02-1.16; P = .008) and per year of cART (RR, 1.11; 95% CI, 1.02-1.21; P = .02).
Conclusions Liver-related death was the most frequent cause of non–AIDS-related death. We found a strong association between immunodeficiency and risk of liver-related death. Longer follow-up is required to investigate whether clinically significant treatment-associated liver-related mortality will develop.
*Authors/Writing Committee: The following members of the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group take authorship responsibility for the D:A:D Study: Rainer Weber, MD; Caroline A. Sabin, PhD; Nina Friis-Møller, MD, PhD; Peter Reiss, MD, PhD; Wafaa M El-Sadr, MD, PhD; Ole Kirk, MD, DMSc; Francois Dabis, MD, PhD; Matthew G. Law, PhD; Christian Pradier, MD, PhD; Stephane De Wit, MD, PhD; Börje Åkerlund, MD; Gonzalo Calvo, MD; Antonella d’Arminio Monforte, MD, DMSc; Martin Rickenbach, MD; Bruno Ledergerber, PhD; Andrew N. Phillips, PhD; and Jens D. Lundgren , MD, DMSc.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Gastrointestinal complications of HIV infection: changing priorities in the HAART era
Wilcox and Saag
Gut 2008;57:861-870.
ABSTRACT
| FULL TEXT
Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial
Soriano et al.
J Antimicrob Chemother 2008;61:200-205.
ABSTRACT
| FULL TEXT
Comorbidities in older patients with HIV: A retrospective study
Magalhaes et al.
Journal of the American Dental Association 2007;138:1468-1475.
ABSTRACT
| FULL TEXT
Improved survival in HIV-infected persons: consequences and perspectives
Lohse et al.
J Antimicrob Chemother 2007;60:461-463.
ABSTRACT
| FULL TEXT
Serious Non-AIDS Conditions: Redefining the Spectrum of HIV-Related Disease
AIDS Clin Care 2007;2007:1-1.
FULL TEXT
Viral hepatitis in HIV infection.
Cross et al.
NEJM 2007;357:90-91.
FULL TEXT
Viral Hepatitis in HIV Infection
Koziel and Peters
NEJM 2007;356:1445-1454.
FULL TEXT
Liver-Related Deaths in HIV Patients
AIDS Clin Care 2006;2006:2-2.
FULL TEXT
|
